Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast-track versus standard radioiodine ablation after thyroidectomy for differentiated thyroid cancer
NL-OMON38352Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Randomised, open-label trial of iodine-131 and thyrotropin alfa in thyroid cancer, well-differentiated thyroid cancer (WDTC) and papillary thyroid cancer (PTC) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Reduction of sick-leave time. Planned start Jul 2012; status: withdrawn.
02
Drugs
iodine-131thyrotropin alfa
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on NL-OMON38352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38352.